Esophageal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight, "Esophageal Cancer Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ Esophageal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Esophageal Cancer Pipeline Report

* In February 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC).
* In February 2025:- Shanghai Henlius Biotech:- The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.
* In February 2025:- AstraZeneca :- This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
* In February 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
* In February 2025:- Janssen Research & Development LLC:- The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
* DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.
* The leading Esophageal Cancer Companies such as BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc ., and others.
* Promising Esophageal Cancer Therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

Stay informed about the cutting-edge advancements in Esophageal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Esophageal Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Cancer Emerging Drugs Profile

* AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

* Tucatinib: Seagen

Tucatinib (TUKYSA Registered ) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

* APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

The Esophageal Cancer pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
* Esophageal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

Get a detailed analysis of the latest innovations in the Esophageal Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Esophageal Cancer Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Cancer Therapeutics Assessment

There are approx. 80+ key Esophageal Cancer companies which are developing the therapies for Esophageal Cancer. The Esophageal Cancer companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

Esophageal Cancer Companies

BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Esophageal Cancer Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming Esophageal Cancer Therapies and key Esophageal Cancer Developments @ Esophageal Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Esophageal Cancer Pipeline Report

* Coverage- Global
* Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc ., and others.
* Esophageal Cancer Therapies- Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

Which companies are leading the race in Esophageal Cancer drug development? Find out in DelveInsight's exclusive Esophageal Cancer Pipeline Report-access it now! @ Esophageal Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Esophageal Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase II/III)
* Tucatinib: Seagen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* APX 005M: Apexigen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Esophageal Cancer Key Companies
* Esophageal Cancer Key Products
* Esophageal Cancer - Unmet Needs
* Esophageal Cancer - Market Drivers and Barriers
* Esophageal Cancer - Future Perspectives and Conclusion
* Esophageal Cancer Analyst Views
* Esophageal Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.